Lumenis, the world’s largest energy-based medical device company for ophthalmic, aesthetic, and surgical application, introduced its first and only FDA-approved intense pulsed light (IPL) device – OptiLight - during the ESCRS Congress on October 9, 2021. The guest speaker was a world-renowned ophthalmologist - Sheraz Daya, MD.
Dry eye disease, also known as keratoconjunctivitis sicca (KCS), is a common disorder that causes dry, gritty, burning, tired eyes and fluctuating vision.
According to the company, about 16 million Americans have been diagnosed, and twice as many may be undiagnosed with dry eye. MGD is the leading cause of dry eye disease, accounting for about 86% of cases.
OptiLight elevates dry eye management with Lumenis’ patented Optimal Pulse Technology (OPT™) and user-centered design. It is referred to as a “Bright Solution for Dry Eyes.”
After receiving greenlight from the FDA back in 2021 as well as its CE marking, the device is proven to significantly improve tear breakup time, meibum quality, and meibomian gland expressibility.
It also reduces the level of pro-inflammatory mediators to inhibit inflammation, destroys the abnormal blood vessels that perpetuate inflammation, and decreases the population of Demodex mites, which stimulate infection and boost the bacterial load on eyelids.
Lumenis is the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF).
OptiLight™ is a new intense pulsed light (IPL) device, with a spectrum of 400-1200 nm, that is indicated for improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV.
IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses.